C
MLYS icon

Covestor’s Mineralys Therapeutics MLYS Stock Holding History

Covestor’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15K Sell
546
-21
-4% -$576 0.01% 1306
2026
Q1 		$15K Buy
567
+94
+20% +$2.76K 0.01% 1230
2025
Q4 		$17K Sell
473
-94
-17% -$3.77K 0.01% 1354
2025
Q3 		$21K Sell
567
-172
-23% -$3.72K 0.01% 1255
2025
Q2 		$10K Buy
+739
New +$10.7K 0.01% 1600

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Covestor's MLYS Position: Q2 2026 in Review

Covestor reduced its Mineralys Therapeutics (MLYS) stake by 3.7% in Q2 2026, selling an estimated $576 and leaving 546 shares worth $15K. The position accounts for 0.01% of the portfolio, ranked #1306.

Covestor first reported a position in MLYS in Q2 2025 and has held it in 5 quarters since. The position peaked at $21K in Q3 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Covestor held 546 shares of Mineralys Therapeutics worth $15K as of Q2 2026.
  • Covestor sold 21 Mineralys Therapeutics shares in Q2 2026, an estimated $576.
  • Mineralys Therapeutics made up 0.01% of Covestor's portfolio in Q2 2026, its #1306 holding.
  • Covestor first reported a position in Mineralys Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Covestor's Mineralys Therapeutics position peaked at $21K in Q3 2025.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.